Molecular genetics and pathogenesis of cardiomyopathy

Journal of Human Genetics

Volumn 61, Issue 1, 2016, Pages 41-50

  Kimura, Akinori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; INTRINSIC FACTOR; CONNECTIN; CONTRACTILE PROTEIN; CYTOSKELETON PROTEIN; TTN PROTEIN, HUMAN;

CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; CYTOSKELETON; DISEASE ASSOCIATION; DNA MODIFICATION; FUNCTIONAL DISEASE; GENE MUTATION; HEART MUSCLE; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; METABOLIC STRESS; MOLECULAR GENETICS; MOLECULAR PATHOLOGY; MUSCLE CONTRACTION; NONHUMAN; PHENOTYPE; REVIEW; GENETICS; MUTATION; SARCOMERE;

CARDIOMYOPATHIES; CONNECTIN; CONTRACTILE PROTEINS; CYTOSKELETAL PROTEINS; HUMANS; MUTATION; SARCOMERES;

EID: 84955502999     PISSN: 14345161     EISSN: 1435232X     Source Type: Journal    
DOI: 10.1038/jhg.2015.83     Document Type: Review

References (144)

1. Maron, B. J., Towbin, J. A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113, 1807-1816 (2006).
2. Towbin, J. A., & Bowles, N. E. The failing heart. Nature 415, 227-233 (2002).
3. Ahmad, F., Seidman, J. G., & Seidman, C. E. The genetic basis for cardiac remodeling. Annu. Rev. Genomics Hum. Genet. 6, 185-216 (2006).
4. Kushwaha, S. S., Fallon, J., & Fuster, V. Restrictive cardiomyopathy. N. Engl. J. Med. 336, 267-276 (1997).
5. Seidman, J. G., & Seidman, C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 104, 557-567 (2001).
6. Goerss, J. B., Michels, V. V., Burnett, J., Driscoll, D. J., Miller, F., Rodeheffer, R., et al. Frequency of familial dilated cardiomyopathy. Eur. Heart J. 16, O2-O4 (1995).
7. Mestroni, L., Rocco, C., Gregori, D., Sinagra, G., Di Lenarda, A., Miocic, S., et al. Familial dilated cardiomyopathy: evidence for genetic and phenotypic heterogeneity. Heart Muscle Disease Study Group. J. Am. Coll. Cardiol. 34, 181-190 (1999).
8. Geisterfer-Lowrance, A. A. T., Kass, S., Tanigawa, G., Vosberg, H. P., McKenna, W., Seidman, C. E., et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 62, 999-1006 (1990).
9. Tanigawa, G., Jarcho, J. A., Kass, S., Solomon, S. D., Vosberg, H. P., Seidman, J. G., et al. A molecular basis for familial hypertrophic cardiomyopathy: an alpha/beta cardiac myosin heavy chain hybrid gene. Cell 62, 991-998 (1990).
10. Watkins, H., Rosenzweig, A., Hwang, D. S., Levi, T., McKenna, W., Seidman, C. E., et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 326, 1108-1114 (1992).
11. Arad, M., Seidman, J. G., & Seidman, C. E. Phenotypic diversity in hypertrophic cardiomyopathy. Hum. Mol. Genet. 11, 2499-2506 (2002).
12. Kimura, A. Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ. J. 72, A38-A48 (2008).
13. Kimura, A. Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J. Hum. Genet. 55, 81-90 (2010).
14. Otsuka, H., Arimura, T., Abe, T., Kawai, H., Aizawa, Y., Kubo, T., et al. Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ. J. 76, 453-461 (2012).
15. Nishi, H., Kimura, A., Harada, H., Adachi, K., Koga, Y., Sasazuki, T., et al. Possible gene dose effect of a mutant cardiac beta-myosin heavy chain gene on the clinical expression of familial hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 200, 549-556 (1994).
16. Kimura, A., Harada, H., Park, J. E., Nishi, H., Satoh, M., Takahashi, M., et al. Mutations in the cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat. Genet. 16, 379-382 (1997).
17. Okada, S., Suzuki, Y., Arimura, T., Kimura, A., Narumi, H., & Hasegawa, S. A novel De novo mutation of β-cardiac myosin heavy chain gene found in a twelve-year-old boy with hypertrophic cardiomyopathy. J. Genet. 93, 557-560 (2014).
18. Olson, T. M., Michels, V. V., Thibodeau, S. N., Tai, Y. S., & Keating, M. T. Actin mutations in dilated cardiomyopathy, a heritable form of heart failure. Science 280, 750-752 (1998).
19. Mogensen, J., Klausen, I. C., Pedersen, A. K., Egeblad, H., Bross, P., Kruse, T. A., et al. Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy. J. Clin. Invest. 103, R39-R43 (1999).
20. Vang, S., Corydon, T. J., Børglum, A. D., Scott, M. D., Frydman, J., Mogensen, J., et al. Actin mutations in hypertrophic and dilated cardiomyopathy cause inefficient protein folding and perturbed filament formation. FEBS J. 272, 2037-2049 (2005).
21. Kamisago, M., Sharma, S. D., DePalma, S. R., Solomon, S., Sharma, P., McDonough, B., et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N. Engl. J. Med. 343, 1688-1696 (2000).
22. Morimoto, S., Lu, Q. W., Harada, K., Takahashi-Yanaga, F., Minakami, R., Ohta, M., et al. Ca(2+)-desensitizing effect of a deletion mutation Delta K210 in cardiac troponin T that causes familial dilated cardiomyopathy. Proc. Natl Acad. Sci. USA 99, 913-918 (2002).
23. Yanaga, F., Morimoto, S., & Ohtsuki, I. Ca2+ sensitization and potentiation of the maximum level of myofibrillar ATPase activity caused by mutations of troponin T found in familial hypertrophic cardiomyopathy. J. Biol. Chem. 274, 8806-8812 (1999).
24. Chang, A. N., & Potter, J. D. Sarcomeric protein mutations in dilated cardiomyopathy. Heart Fail. Rev. 10, 225-235 (2005).
25. Sweeney, H. L., Straceski, A. J., Leinwand, L. A., Tikunov, B. A., & Faust, L. Heterologous expression of a cardiomyopathic myosin that is defective in its actin interaction. J. Biol. Chem. 269, 1603-1605 (1994).
26. Thierfelder, L., Watkins, H., MacRae, C., Lamas, R., McKenna, W., Vosberg, H. P., et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 77, 701-712 (1994).
27. Bottinelli, R., Coviello, D. A., Redwood, C. S., Pellegrino, M. A., Maron, B. J., Spirito, P., et al. A mutant tropomyosin that causes hypertrophic cardiomyopathy is expressed in vivo and associated with an increased calcium sensitivity. Circ. Res. 82, 106-115 (1998).
28. Elliott, K., Watkins, H., & Redwood, C. S. Altered regulatory properties of human cardiac troponin I mutants that cause hypertrophic cardiomyopathy. J. Biol. Chem. 275, 22069-22074 (2000).
29. Witt, C. C., Gerull, B., Davies, M. J., Centner, T., Linke, W. A., & Thierfelder, L. Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C. J. Biol. Chem. 276, 5353-5359 (2001).
30. Roopnarine, O. Mechanical defects of muscle fibers with myosin light chain mutants that cause cardiomyopathy. Biophys. J. 84, 2440-2449 (2003).
31. Pinto, J. R., Parvatiyar, M. S., Jones, M. A., Liang, J., Ackerman, M. J., & Potter, J. D. A functional and structural study of troponin C mutations related to hypertrophic cardiomyopathy. J. Biol. Chem. 284, 19090-19100 (2009).
32. Tyska, M. J., Hayes, E., Giewat, M., Seidman, C. E., Seidman, J. G., & Warshaw, D. M. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ. Res. 86, 737-744 (2000).
33. Tadano, N., Morimoto, S., Yoshimura, A., Miura, M., Yoshioka, K., Sakato, M., et al. SCH00013, a novel Ca(2+) sensitizer with positive inotropic and no chronotropic action in heart failure. J. Pharmacol. Sci. 97, 53-60 (2005).
34. Satoh, M., Takahashi, M., Sakamoto, T., Hiroe, M., Marumo, F., & Kimura, A. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem. Biophys. Res. Commun. 262, 411-417 (1999).
35. Hayashi, T., Arimura, T., Itoh-Satoh, M., Ueda, K., Hohda, S., Inagaki, N., et al. Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J. Am. Coll. Cardiol. 44, 2192-2201 (2004).
36. Cazorla, O., Wu, Y., Irving, T. C., & Granzier, H. Titin-based modulation of calcium sensitivity of active tension in mouse skinned cardiac myocytes. Circ. Res. 88, 1028-1035 (2001).
37. Fujita, H., Labeit, D., Gerull, B., Labeit, S., & Granzier, H. L. Titin isoform-dependent effect of calcium on passive myocardial tension. Am. J. Physiol. Heart Circ. Physiol. 287, H2528-H2534 (2004).
38. Fuchs, F., & Martyn, D. A. Length-dependent Ca(2+) activation in cardiac muscle: some remaining questions. J. Muscle Res. Cell Motil. 26, 199-212 (2005).
39. Geier, C., Perrot, A., Ozcelik, C., Binner, P., Counsell, D., Hoffmann, K., et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 107, 1390-1395 (2003).
40. Gehmlich, K., Geier, C., Osterziel, K. J., Van Der Ven, P. F., & Fürst, D. O. Decreased interactions of mutant muscle LIM protein (MLP) with N-RAP and alpha-Actinin and their implication for hypertrophic cardiomyopathy. Cell. Tissue Res. 317, 129-136 (2004).
41. Mohapatra, B., Jimenez, S., Lin, J. H., Bowles, K. R., Coveler, K. J., Marx, J. G., et al. Mutations in the muscle LIM protein and alpha-Actinin-2 genes in dilated cardiomyopathy and endocardial fibroelastosis. Mol. Genet. Metab. 80, 207-215 (2003).
42. Itoh-Satoh, M., Hayashi, T., Nishi, H., Koga, Y., Arimura, T., Koyanagi, T., et al. Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 291, 385-393 (2002).
43. Gerull, B., Gramlich, M., Atherton, J., McNabb, M., Trombitás, K., Sasse-Klaassen, S., et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 30, 201-204 (2002).
44. Knöll, R., Hoshijima, M., Hoffman, H. M., Person, V., Lorenzen-Schmidt, I., Bang, M. L., et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell 111, 943-955 (2002).
45. Knöll, R., Kostin, S., Klede, S., Savvatis, K., Klinge, L., Stehle, I., et al. A common MLP (muscle LIM protein) variant is associated with cardiomyopathy. Circ. Res. 106, 695-704 (2010).
46. Zhou, Q., Ruiz-Lozano, P., Martone, M. E., & Chen, J. Cypher, a striated musclerestricted PDZ and LIM domain-containing protein, binds to alpha-Actinin-2 and protein kinase C. J. Biol. Chem. 274, 19807-19813 (1999).
47. Frey, N., Richardson, J. A., & Olson, E. N. Calsarcins, a novel family of sarcomeric calcineurin-binding proteins. Proc. Natl Acad. Sci. USA 97, 14632-14637 (2000).
48. Heineke, J., & Molkentin, J. D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell. Biol. 7, 589-600 (2006).
49. Heineke, J., Ruetten, H., Willenbockel, C., Gross, S. C., Naguib, M., Schaefer, A., et al. Attenuation of cardiac remodeling after myocardial infarction by muscle LIM proteincalcineurin signaling at the sarcomeric Z-disc. Proc. Natl Acad. Sci. USA 102, 1655-1660 (2005).
50. Arimura, T., Hayashi, T., Terada, H., Lee, S. Y., Zhou, Q., Takahashi, M., et al. A Cypher/ZASP mutation associated with dilated cardiomyopathy alters the binding affinity to protein kinase C. J. Biol. Chem. 279, 6746-6752 (2004).
51. Vatta, M., Mohapatra, B., Jimenez, S., Sanchez, X., Faulkner, G., Perles, Z., et al. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol. 42, 2014-2027 (2003).
52. Arimura, T., Inagaki, N., Hayashi, T., Shichi, D., Sato, A., Hinohara, K., et al. Impaired binding of ZASP/Cypher with phosphoglucomutase 1 is associated with dilated cardiomyopathy. Cardiovasc. Res. 83, 80-88 (2009).
53. Li, D., Tapscoft, T., Gonzalez, O., Burch, P. E., Quiñones, M. A., Zoghbi, W. A., et al. Desmin mutation responsible for idiopathic dilated cardiomyopathy. Circulation 100, 461-464 (1999).
54. Olson, T M., Illenberger, S., Kishimoto, N. Y., Huttelmaier, S., Keating, M. T., & Jockusch, B. M. Metavinculin mutations alter actin interaction in dilated cardiomyopathy. Circulation 105, 431-437 (2002).
55. Taylor, M. R., Slavov, D., Ku, L., Di Lenarda, A., Sinagra, G., Carniel, E., et al. Prevalence of desmin mutations in dilated cardiomyopathy. Circulation 115, 1244-1251 (2007).
56. Duboscq-Bidot, L., Xu, P., Charron, P., Neyroud, N., Dilanian, G., Millaire, A., et al. Mutations in the Z-band protein myopalladin gene and idiopathic dilated cardiomyopathy. Cardiovasc. Res. 77, 118-125 (2008).
57. Granzier, H. L., & Labeit, S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ. Res. 94, 284-295 (2004).
58. Herman, D. S., Lam, L., Taylor, M. R., Wang, L., Teekakirikul, P., Christodoulou, D., et al. Truncations of titin causing dilated cardiomyopathy. N. Engl. J. Med. 366, 619-628 (2012).
59. Norton, N., Li, D., Rampersaud, E., Morales, A., Martin, E. R., Zuchner, S., et al. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ. Cardiovasc. Genet. 6, 144-153 (2013).
60. Golbus, J. R., Puckelwartz, M. J., Fahrenbach, J. P., Dellefave-Castillo, L. M., Wolfgeher, D., & McNally, E. M. Population-based variation in cardiomyopathy genes. Circ. Cardiovasc. Genet. 5, 391-399 (2012).
61. Roberts, A. M., Ware, J. S., Herman, D. S., Schafer, S., Baksi, J., Bick, A. G., et al. Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. Sci. Transl. Med. 7, 270 (2015).
62. Towbin, J. A., Hejtmancik, J. F., Brink, P., Gelb, B., Zhu, X. M., Chamberlain, J. S., et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation 87, 1854-1865 (1993).
63. Cohen, N., & Muntoni, F. Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy. Heart 90, 835-841 (2004).
64. Muntoni, F., Torelli, S., & Ferlini, A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol. 2, 731-740 (2003).
65. Finsterer, J., & Stöllberger, C. The heart in human dystrophinopathies. Cardiology 99, 1-19 (2003).
66. Lapidos, K. A., Kakkar, R., & McNally, E. M. The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ. Res. 94, 1023-1031 (2004).
67. Tsubata, S., Bowles, K. R., Vatta, M., Zintz, C., Titus, J., Muhonen, L., et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. J. Clin. Invest. 106, 655-662 (2000).
68. Knöll, R., Postel, R., Wang, J., Krätzner, R., Hennecke, G., Vacaru, A. M., et al. Laminin-Alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation 116, 515-525 (2007).
69. Hayashi, T., Arimura, T., Ueda, K., Shibata, H., Hohda, S., Takahashi, M., et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 313, 178-184 (2004).
70. Vasile, V. C., Ommen, S. R., Edwards, W. D., & Ackerman, M. J. A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 345, 998-1003 (2006).
71. Wang, X., Osinska, H., Klevitsky, R., Gerdes, A. M., Nieman, M., Lorenz, J., et al. Expression of R120G-AlphaB-crystallin causes aberrant desmin and alphaB-crystallin aggregation and cardiomyopathy in mice. Circ. Res. 89, 84-91 (2001).
72. Landstrom, A. P., Weisleder, N., Batalden, K. B., Bos, J. M., Tester, D. J., Ommen, S. R., et al. Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic cardiomyopathy in humans. J. Mol. Cell Cardiol. 42, 1026-1035 (2007).
73. Arimura, T., Matsumoto, Y., Okazaki, O., Hayashi, T., Takahashi, M., Inagaki, N., et al. Structural analysis of obscurin gene in hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 362, 281-287 (2007).
74. Arimura, T., Bos, M. J., Sato, A., Kubo, T., Okamoto, H., Nishi, H., et al. Cardiac ankyrin repeat protein gene (ANKRD1) mutations in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 54, 334-342 (2009).
75. Rajasekaran, N. S., Connell, P., Christians, E. S., Yan, L. J., Taylor, R. P., Orosz, A., et al. Human alpha B-crystallin mutation causes oxido-reductive stress and protein aggregation cardiomyopathy in mice. Cell 130, 427-439 (2007).
76. Matsumoto, Y., Hayashi, T., Inagaki, N., Takahashi, M., Hiroi, S., Nakamura, T., et al. Functional analysis of titin/connectin N2-B mutations found in cardiomyopathy. J. Muscle Res. Cell Motil. 26, 367-374 (2005).
77. Inagaki, N., Hayashi, T., Arimura, T., Koga, Y., Takahashi, M., Shibata, H., et al. Alpha B-crystallin mutation in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 342, 379-386 (2006).
78. Young, P., Ehler, E., & Gautel, M. Obscurin, a giant sarcomeric Rho guanine nucleotide exchange factor protein involved in sarcomere assembly. J. Cell. Biol. 154, 123-136 (2001).
79. Aihara, Y., Kurabayashi, M., Saito, Y., Ohyama, Y., Tanaka, T., Takeda, S., et al. Cardiac ankyrin repeat protein is a novel marker of cardiac hypertrophy: role of M-CAT element within the promoter. Hypertension 36, 48-53 (2000).
80. Witt, S. H., Labeit, D., Granzier, H., Labeit, S., & Witt, C. C. Dimerization of the cardiac ankyrin protein CARP: Implications for MARP titin-based signaling. J. Muscle Res. Cell. Motil. 262, 1-8 (2006).
81. Crocini, C., Arimura, T., Reischmann, S., Eder, A., Braren, I., Hansen, A., et al. Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue. Basic Res. Cardiol. 108, 349 (2013).
82. Fatkin, D., MacRae, C., Sasaki, T., Wolff, M. R., Porcu, M., Frenneaux, M., et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N. Engl. J. Med. 341, 1715-1724 (1999).
83. Bonne, G., Di Barletta, M. R., Varnous, S., Bécane, H. M., Hammouda, E. H., Merlini, L., et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat. Genet. 21, 285-288 (1999).
84. Bione, S., Small, K., Aksmanovic, V. M., D'Urso, M., Ciccodicola, A., Merlini, L., et al. Identification of new mutations in the Emery-Dreifuss muscular dystrophy gene and evidence for genetic heterogeneity of the disease. Hum. Mol. Genet. 4, 1859-1863 (1995).
85. Morris, G. E., & Manilal, S. Heart to heart: from nuclear proteins to Emery-Dreifuss muscular dystrophy. Hum. Mol. Genet. 8, 1847-1851 (1999).
86. Sylvius, N., & Tesson, F. Lamin A/C and cardiac diseases. Curr. Opin. Cardiol. 21, 159-165 (2006).
87. Arimura, T., Helbling-Leclerc, A., Massart, C., Varnous, S., Niel, F., Lacène, E., et al. Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. Hum. Mol. Genet. 14, 155-169 (2005).
88. Muchir, A., Pavlidis, P., Decostre, V., Herron, A. J., Arimura, T., Bonne, G., et al. Activation of MAPK pathways links LMNA mutations to cardiomyopathy in Emery- Dreifuss muscular dystrophy. J. Clin. Invest. 117, 1282-1293 (2007).
89. Bienengraeber, M., Olson, T. M., Selivanov, V. A., Kathmann, E. C., O'Cochlain, F., Gao, F., et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat. Genet. 36, 382-387 (2004).
90. McNair, W. P., Ku, L., Taylor, M. R., Fain, P. R., Dao, D., Wolfel, E., et al. SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia. Circulation 110, 2163-2167 (2004).
91. Lehnart, S. E., Ackerman, M. J., Benson, D. W. Jr., Brugada, R., Clancy, C. E., Donahue, J. K., et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyopathies of gene mutations affecting ion channel function. Circulation 116, 2325-2345 (2007).
92. Arimura, T., Hayashi, T., Matsumoto, Y., Shibata, H., Hiroi, S., Nakamura, T., et al. Structural analysis of four and half LIM protein-2 in dilated cardiomyopathy. Biochem. Biophys. Res. Commun. 357, 162-167 (2007).
93. Johannessen, M., Møller, S., Hansen, T., Moens, U., & Van Ghelue, M. The multifunctional roles of the four-And-A-half-LIM only protein FHL2. Cell Mol. Life Sci. 63, 268-284 (2006).
94. Hoshijima, M., Knöll, R., Pashmforoush, M., & Chien, K. R. Reversal of calcium cycling defects in advanced heart failure toward molecular therapy. J. Am. Coll. Cardiol. 48, A15-A23 (2006).
95. Schmitt, J. P., Kamisago, M., Asahi, M., Li, G. H., Ahmad, F., Mende, U., et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410-1413 (2003).
96. Haghighi, K., Kolokathis, F., Gramolini, A. O., Waggoner, J. R., Pater, L., Lynch, R. A., et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl Acad. Sci. USA 103, 1388-1393 (2006).
97. Chiu, C., Tebo, M., Ingles, J., Yeates, L., Arthur, J. W., Lind, J. M., et al. Genetic screening of calcium regulation genes in familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 43, 337-343 (2007).
98. Koss, K. L., Grupp, I. L., & Kranias, E. G. The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic. Res. Cardiol. 92, S17-S24 (1997).
99. Minamisawa, S., Hoshijima, M., Chu, G., Ward, C. A., Frank, K., Gu, Y., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99, 313-322 (1999).
100. Hoshijima, M., Ikeda, Y., Iwanaga, Y., Minamisawa, S., Date, M. O., Gu, Y., et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864-871 (2002).
101. Nigro, V., Okazaki, Y., Belsito, A., Piluso, G., Matsuda, Y., Politano, L., et al. Identification of the Syrian hamster cardiomyopathy gene. Hum. Mol. Genet. 6, 601-607 (1997).
102. Minamisawa, S., Sato, Y., Tatsuguchi, Y., Fujino, T., Imamura, S., Uetsuka, Y., et al. Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 304, 1-4 (2003).
103. Medin, M., Hermida-Prieto, M., Monserrat, L., Laredo, R., Rodriguez-Rey, J. C., Fernandez, X., et al. Mutational screening of phospholamban gene in hypertrophic and idiopathic dilated cardiomyopathy and functional study of the PLN -42 C4G mutation. Eur. J. Heart Fail. 9, 37-43 (2007).
104. Arimura, T., Takeya, R., Ishikawa, T., Yamano, T., Matsuo, A., Tatsumi, T., et al. Dilated cardiomyopathy-Associated FHOD3 variant impairs the ability to induce activation of transcription factor serum response factor. Circ. J. 77, 2990-2996 (2013).
105. Norton, N., Li, D., Rieder, M. J., Siegfried, J. D., Rampersaud, E., Züchner, S., et al. Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am. J. Hum. Genet. 88, 273-282 (2011).
106. Arimura, T., Ishikawa, T., Nunoda, S., Kawai, S., & Kimura, A. Dilated cardiomyopathyassociated BAG3 mutations impair Z-disc assembly and enhance sensitivity to apoptosis in cardiomyocytes. Hum. Mutat. 32, 1481-1491 (2011).
107. Barth, P. G., Valianpour, F., Bowen, V. M., Lam, J., Duran, M., Vaz, F. M., et al. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome): an update. Am. J. Med. Genet. A 126, 349-354 (2004).
108. Murakami, T., Hayashi, Y. K., Noguchi, S., Ogawa, M., Nonaka, I., Tanabe, Y., et al. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Ann. Neurol. 60, 597-602 (2006).
109. Norgett, E. E., Hatsell, S. J., Carvajal-Huerta, L., Cabezas, J. C., Common, J., Purkis, P. E., et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum. Mol. Genet. 9, 2761-2766 (2000).
110. Uzumcu, A., Norgett, E. E., Dindar, A., Uyguner, O., Nisli, K., Kayserili, H., et al. Loss of desmoplakin isoform I causes early onset cardiomyopathy and heart failure in a Naxos-like syndrome. J. Med. Genet. 43, e5 (2006).
111. Arimura, T., Hayashi, Y. K., Murakami, T., Oya, Y., Funabe, S., Hirasawa, E. A., et al. Mutational analysis of fukutin gene in dilated cardiomyopathy and hypertrophic cardiomyopathy. Circ. J. 73, 158-161 (2009).
112. Marian, A. J., & Roberts, R. The molecular genetic basis for hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 33, 655-670 (2001).
113. Marian, A. J. Modifier genes for hypertrophic cardiomyopathy. Curr. Opin. Cardiol. 17, 242-252 (2002).
114. Jacoby, D., & McKenna, W. J. Genetics of inherited cardiomyopathy. Eur. Heart J. 33, 296-304 (2012).
115. Brugada, R., Kelsey, W., Lechin, M., Zhao, G., Yu, Q. T., Zoghbi, W., et al. Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J. Investig. Med. 45, 542-551 (1997).
116. Semsarian, C., Healey, M. J., Fatkin, D., Giewat, M., Duffy, C., Seidman, C. E., et al. A polymorphic modifier gene alters the hypertrophic response in a murine model of familial hypertrophic cardiomyopathy. J. Mol. Cell. Cardiol. 33, 2055-2060 (2001).
117. Christodoulou, D. C., Wakimoto, H., Onoue, K., Eminaga, S., Gorham, J. M., DePalma, S. R., et al. 5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy. J. Clin. Invest. 124, 1364-1370 (2014).
118. Suzuki, M., Carlson, K M., Marchuk, D. A., & Rockman, H. A. Genetic modifier loci affecting survival and cardiac function in murine dilated cardiomyopathy. Circulation 105, 1824-1829 (2002).
119. Le Corvoisier, P., Park, H. Y., Carlson, K. M., Marchuk, D. A., & Rockman, H. A. Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy. Hum. Mol. Genet. 12, 3097-3107 (2003).
120. Wheeler, F. C., Fernandez, L., Carlson, K. M., Wolf, M. J., Rockman, H. A., & Marchuk, D. A. QTL mapping in a mouse model of cardiomyopathy reveals an ancestral modifier allele affecting heart function and survival. Mamm. Genome 16, 414-423 (2005).
121. Wheeler, F. C., Tang, H., Marks, O. A., Hadnott, T. N., Chu, P. L., Mao, L., et al. Tnni3k modifies disease progression in murine models of cardiomyopathy. PLoS Genet. 5, e1000647 (2009).
122. Kubo, T., Kitaoka, H., Okawa, M., Yamanaka, S., Hirota, T., Hoshikawa, E., et al. Serum cardiac troponin I is related to increased left ventricular wall thickness, left ventricular dysfunction, and male gender in hypertrophic cardiomyopathy. Clin. Cardiol. 33, E1-E7 (2010).
123. Van Rijsingen, I. A., Nannenberg, E. A., Arbustini, E., Elliott, P. M., Mogensen, J., Hermans-van Ast, J. F., et al. Gender-specific differences in major cardiac events and mortality in lamin A/C mutation carriers. Eur. J. Heart Fail. 15, 376-384 (2013).
124. Arimura, T., Onoue, K., Takahashi-Tanaka, Y., Ishikawa, T., Kuwahara, M., Setou, M., et al. Nuclear accumulation of androgen receptor in gender difference of dilated cardiomyopathy due to lamin A/C mutations. Cardiovasc. Res. 99, 382-394 (2013).
125. Bertrand, A. T., Renou, L., Papadopoulos, A., Beuvin, M., Lacène, E., Massart, C., et al. DelK32-lamin A/C has abnormal location and induces incomplete tissue maturation and severe metabolic defects leading to premature death. Hum. Mol. Genet. 21, 1037-1048 (2012).
126. Pinto, J. R., Parvatiyar, M. S., Jones, M. A., Liang, J., & Potter, J. D. A troponin T mutation that causes infantile restrictive cardiomyopathy increases Ca2+ sensitivity of force development and impairs the inhibitory properties of troponin. J. Biol. Chem. 283, 2156-2166 (2008).
127. Yumoto, F., Lu, Q. W., Morimoto, S., Tanaka, H., Kono, N., Nagata, K., et al. Drastic Ca2+ sensitization of myofilament associated with a small structural change in troponin I in inherited restrictive cardiomyopathy. Biochem. Biophys. Res. Commun. 338, 1519-1526 (2005).
128. Kubo, T., Gimeno, J. R., Bahl, A., Steffensen, U., Steffensen, M., Osman, E., et al. Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. J. Am. Coll. Cardiol. 49, 2419-2426 (2007).
129. Mogensen, J., Kubo, T., Duque, M., Uribe, W., Shaw, A., Murphy, R., et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111, 209-216 (2003).
130. Murphy, R T., Mogensen, J., Shaw, A., Kubo, T., Hughes, S., & McKenna, W. J. Novel mutation in cardiac troponin I in recessive idiopathic dilated cardiomyopathy. Lancet 363, 371-372 (2004).
131. Budde, B. S., Binner, P., Waldmüller, S., Höhne, W., Blankenfeldt, W., Hassfeld, S., et al. Noncompaction of the ventricular myocardium is associated with a De novo mutation in the beta-myosin heavy chain gene. PLoS ONE 2, e1362 (2007).
132. Monserrat, L., Hermida-Prieto, M., Fernandez, X., Rodríguez, I., Dumont, C., Cazón, L., et al. Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular non-compaction, and septal defects. Eur. Heart J. 28, 1953-1961 (2007).
133. Hermida-Prieto, M., Monserrat, L., Castro-Beiras, A., Laredo, R., Soler, R., Peteiro, J., et al. Familial dilated cardiomyopathy and isolated left ventricular noncompaction associated with lamin A/C gene mutations. Am. J. Cardiol. 94, 50-54 (2004).
134. Bleyl, S. B., Mumford, B. R., Thompson, V., Carey, J. C., Pysher, T. J., Chin, T. K., et al. Neonatal, lethal noncompaction of the left ventricular myocardium is allelic with Barth syndrome. Am. J. Hum. Genet. 61, 868-872 (1997).
135. Ichida, F., Tsubata, S., Bowles, K. R., Haneda, N., Uese, K., Miyawaki, T., et al. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103, 1256-1263 (2001).
136. Chen, H., Shi, S., Acosta, L., Li, W., Lu, J., Bao, S., et al. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 131, 2219-2231 (2004).
137. Neuhaus, H., Rosen, V., & Thies, R. S. Heart specific expression of mouse BMP-10 a novel member of the TGF-beta superfamily. Mech. Dev. 80, 181-184 (1999).
138. Van Tintelen, J. P., Hofstra, R. M., Wiesfeld, A. C., Van den Berg, M. P., Hauer, R. N., & Jongbloed, J. D. Molecular genetics of arrhythmogenic right ventricular cardiomyopathy: emerging horizon?. Curr. Opin. Cardiol. 22, 185-192 (2007).
139. McKoy, G., Protonotarios, N., Crosby, A., Tsatsopoulou, A., Anastasakis, A., Coonar, A., et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 355, 2119-2124 (2000).
140. Alcalai, R., Metzger, S., Rosenheck, S., Meiner, V., & Chajek-Shaul, T. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J. Am. Coll. Cardiol. 42, 319-327 (2003).
141. Gerull, B., Heuser, A., Wichter, T., Paul, M., Basson, C. T., McDermott, D. A., et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat. Genet. 36, 1162-1164 (2004).
142. Pilichou, K., Nava, A., Basso, C., Beffagna, G., Bauce, B., Lorenzon, A., et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 113, 1171-1179 (2006).
143. Tiso, N., Stephan, D. A., Nava, A., Bagattin, A., Devaney, J. M., Stanchi, F., et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum. Mol. Genet. 10, 189-194 (2001).
144. Beffagna, G., Occhi, G., Nava, A., Vitiello, L., Ditadi, A., Basso, C., et al. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc. Res. 65, 366-373 (2005).